Evidence map›Paper›PMID 32488672›Full record

Trial reportPediatric nephrology (Berlin, Germany)2020

Prevalence of acute kidney injury (AKI) in extremely low gestational age neonates (ELGAN).

David J Askenazi, Patrick J Heagerty, Robert H Schmicker, Russell Griffin, Patrick Brophy, Sandra E Juul, Dennis E Mayock, Stuart L Goldstein, Sangeeta Hingorani, PENUT Trial Consortium

Open access · greenAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Pediatric nephrology (Berlin, Germany), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 60 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
60citing papers in PubMed, 4 pooled it
6.1field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

60 citing papers in PubMed, 4 syntheses or guidelines pooled it, 91 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Trial
  7. Acute kidney injury and subsequent risk of late-onset infection among extremely low gestational age newborns.Journal of perinatology : official journal of the California Perinatal Association · 2025
    Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Observational
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 1 country.

David J AskenaziDepartment of Pediatrics, University of Alabama at Birmingham, Birmingham, AL, USA. daskenazi@peds.uab.edu.
Patrick J HeagertyDepartment of Biostatistics, University of Washington, Seattle, WA, USA.
Robert H SchmickerDepartment of Biostatistics, University of Washington, Seattle, WA, USA.
Russell GriffinDepartment of Epidemiology, University of Alabama at Birmingham, Birmingham, AL, USA.
Patrick BrophyUniversity of Rochester/Golisano Children's Hospital, Rochester, NY, USA.
Sandra E JuulDepartment of Pediatrics, University of Washington/Seattle Children's Hospital, Seattle, WA, USA.
Dennis E MayockDepartment of Pediatrics, University of Washington/Seattle Children's Hospital, Seattle, WA, USA.
Stuart L GoldsteinDepartment of Pediatrics, Cincinnati Children's Hospital Medical Center/University of Cincinnati College of Medicine, Cincinnati, OH, 45267, USA.
Sangeeta HingoraniDepartment of Pediatrics, University of Washington/Seattle Children's Hospital, Seattle, WA, USA.
PENUT Trial Consortium
University of Washington · USUniversity of Alabama at Birmingham · USCincinnati Children's Hospital Medical Center · USGolisano Children's Hospital · USSeattle Children's Hospital · US

Funding

UAB Center for Clinical and Translational Science (CCTS)UL1TR001417 · NCATS · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI KIMBERLY, ROBERT P. · 2015 to 2018
$31.4M
Preterm Epo Neuroprotection Trial (PENUT Trial) CCCU01NS077953 · NINDS · UNIVERSITY OF WASHINGTON · PI JUUL, SANDRA E · 2013 to 2018
$10.7M
Recombinant Erythropoietin for Protection of Infant Renal Disease(REPAIReD)R01DK103608 · NIDDK · SEATTLE CHILDREN'S HOSPITAL · PI ASKENAZI, DAVID JOSEPH, GOLDSTEIN, STUART L · 2014 to 2019
$3.0M
Preterm Epo Neuroprotection Trial (PENUT Trial) DCCU01NS077955 · NINDS · UNIVERSITY OF WASHINGTON · PI HEAGERTY, PATRICK J · 2013 to 2018
$1.5M
Phase 2 Study of Selective Cytopheretic Device for the Treatment of Pediatric Patients with Acute Kidney Injury R01FD005092 · FDA · INNOVATIVE BIOTHERAPIES, INC. · PI GOLDSTEIN, STUART L, HUMES, H. DAVID · 2015 to 2018
$976k
Acute Renal Injury Sequelae in NICU Graduates (ARISING)U34DK117128 · NIDDK · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI AMBALAVANAN, NAMASIVAYAM, ASKENAZI, DAVID JOSEPH · 2019 to 2020
$754k
FDA HHS R01 FD005092NCATS NIH HHS UL1 TR001417NIDDK NIH HHS R01 DK103608NIDDK NIH HHS U34 DK117128NINDS NIH HHS U01 NS077953NINDS NIH HHS U01 NS077955
6 · The paper itself

Abstract

backgroundTo determine the prevalence and severity of acute kidney injury (AKI) at different time frames in relation to gestational age (GA) and birthweight (BW) in extremely low gestational age neonates (ELGAN). Our hypothesis is that ELGAN with lower GA and lower BW have higher AKI rates.

methodsA total of 923 ELGAN enrolled in the Preterm Erythropoietin Neuroprotection Trial were evaluated from birth until death or hospital discharge. AKI was defined according to kidney disease: improving global outcomes (KDIGO) definition from clinically-derived serum creatinine (SCr) measurements. Severe AKI was defined as stage 2 or higher.

resultsFor the entire cohort, 351/923 (38.0%, CI = 34.8-41.3%) had at least one episode of stage 1 or higher AKI and 168/923 (18.2%, CI = 15.7-20.7%) had at least one episode of severe (stage 2 or higher) AKI. The prevalence of AKI stage 1 or higher for the entire cohort during the early (days 3-7), middle (days 8-14), and late follow-up period (after day 14) was 112/923 (12.1%, CI = 10.0-14.3%), 142/891 (15.9%, CI = 13.5-18.4%), and 249/875 (28.5%, CI = 25.4-31.5%), respectively. The rates of severe AKI during the hospital course were 27.8%, 21.9%, 13.6%, and 9.4% for the 24-, 25-, 26-, and 27-week GA groups, respectively. AKI rates were significantly higher with decreasing GA and decreasing BW for stated time trends (all p < 0.01 using tests for trend).

conclusionsAKI is relatively common in ELGAN during their initial hospital course and is associated with lower GA and BW.

Indexed as

Infant, Extremely Low Birth WeightAcute Kidney InjuryCreatinineDouble-Blind MethodFemaleGestational AgeHumansInfant, Extremely PrematureInfant, NewbornIntensive Care Units, NeonatalMalePrevalenceCreatinineAcute renal failureCystatin cIncidenceNeonatePrematureTiming

Identifiers

PMID32488672
PMCPMC8093091
OpenAlexW3030580525

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.